In infertile females having polycystic ovary syndrome and undergoing in vitro fertilization, 200 μg/day of Selenium supplementation improved glycemic control and malondialdehyde levels.

A randomized, double-blind, placebo-controlled research examined the impact of Selenium intake on the metabolic profile of infertile women with polycystic ovarian syndrome (PCOS).

Overall, 40 PCOS-positive infertile females 18 to 40 years old were divided into two treatment groups at random and given either placebo (starch) or Selenium supplementation (200 μg/day). At baseline and eight weeks following treatment, collection of fasting blood samples was done.

Selenium supplementation substantially reduced fasting glucose, levels of fasting insulin, and the homeostasis model evaluation for insulin resistance, and increased quantitative insulin sensitivity check index. Malondialdehyde (MDA) levels also decreased considerably by Selenium administration. Supplemental Selenium had no discernible effects on levels of total glutathione, total antioxidant capacity, lipid profiles, or rate of pregnancy.

Eight-week Selenium supplementation showed positive impacts on MDA levels and glycemic control in PCOS-afflicted infertile women undergoing IVF.